Large Risk Reduction For Rivaroxaban In Blood Clot Prevention
/
RSS Feed
Bengt Eriksson
REFERENCE: Abstract 6, American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta
BENGT ERIKSSON, Gothenburg University
In a large phase III trial of patients having a hip replacement, the oral anticoagulant rivaroxaban has shown significant benefit when compared to enoxaparin. Derek Thorne heard more from Bengt Eriksson of Gothenburg University.
BENGT ERIKSSON, Gothenburg University
In a large phase III trial of patients having a hip replacement, the oral anticoagulant rivaroxaban has shown significant benefit when compared to enoxaparin. Derek Thorne heard more from Bengt Eriksson of Gothenburg University.
You may also like...
Best Evidence Yet that Folic Acid Fortification Reduces Neural-Tube Defects 2 Aug, 2007 - Ovarian Stimulation Does Not Affect Fetal Birth Weight – reporting from 23rd Annual Conference of the European Society of Human Reproduction and Embryology, 1-4 July 2007, Lyon, France 2 Aug, 2007
- Broad Approach, Including Computer System, to Improve Hospital Hygiene 23 Sep, 2007
- Audio Journal of Hematologic Malignancy Special Edition 2005 14 Jan, 2006
I am a medicine student in Turkey and I am hoping to have my specialty in Orthotics. I am really glad to listen such a nice podcast about current progresses in the field, I hope I can make similar research in the field as well.